IRVINE, Calif., May 11, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, reported today that total revenues for the first quarter of 2012 increased 36% to $1.2 million from $913,000 in the first quarter of 2011. The Company performed a total of 1,377 billable diagnostic tests for 105 customers in the first quarter of 2012, compared to 958 tests for 86 customers in the first quarter of 2011.
